Neeraj Agarwal, Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute (HCI), shared a post on X about a recent article he and his colleagues co-authored, adding:
“Just in Nature Medicine results from the Phase 3 AMPLITUDE trial:
- Adding niraparib to abiraterone increased outcomes in HRR-altered mHSPC prostate cancer
- RPFS increased: BRCA 1/2 HR 0.52, P < 0.0001; ITT HR 0.63, P =0.0001.”
Title: Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial
Authors: Gerhardt Attard, Neeraj Agarwal, Julie N. Graff, Shahneen Sandhu, Eleni Efstathiou, Mustafa Özgüroğlu, Andrea J. Pereira de Santana Gomes, Karina Vianna, Hong Luo, Geoffrey T. Gotto, Heather H. Cheng, Won Kim, Carly R. Varela, Daneen Schaeffer, Kassie Kramer, Susan Li, Benoit Baron, Fei Shen, Suneel D. Mundle, Sharon A. McCarthy, David Olmos, Kim N. Chi, Dana E. Rathkopf
Read the Full Article on Nature Medicine
More posts featuring Neeraj Agarwal.
